Mary Collier

713 total citations
25 papers, 557 citations indexed

About

Mary Collier is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Mary Collier has authored 25 papers receiving a total of 557 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 9 papers in Molecular Biology. Recurrent topics in Mary Collier's work include Cancer Treatment and Pharmacology (10 papers), Colorectal Cancer Treatments and Studies (5 papers) and Peptidase Inhibition and Analysis (5 papers). Mary Collier is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Colorectal Cancer Treatments and Studies (5 papers) and Peptidase Inhibition and Analysis (5 papers). Mary Collier collaborates with scholars based in United States, United Kingdom and Spain. Mary Collier's co-authors include Neil J. Clendeninn, Anthony Elias, Lynn G. Feun, Xin Huang, Kathy D. Miller, Kenneth A. Kern, Linda J. Paradiso, Yazdi K. Pithavala, Charles M. Baum and Wayne D. Brenckman and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Mary Collier

25 papers receiving 545 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mary Collier United States 15 331 230 155 128 85 25 557
N. J. Vogelzang United States 16 302 0.9× 286 1.2× 290 1.9× 89 0.7× 66 0.8× 38 759
David D. Gibbs New Zealand 8 213 0.6× 198 0.9× 173 1.1× 58 0.5× 60 0.7× 15 514
Antonella Ingrosso Italy 14 244 0.7× 192 0.8× 163 1.1× 81 0.6× 39 0.5× 25 635
J. Luz Tovar García Colombia 7 275 0.8× 145 0.6× 140 0.9× 68 0.5× 73 0.9× 8 591
Katherine A. Shackelford United States 8 363 1.1× 303 1.3× 353 2.3× 66 0.5× 47 0.6× 10 741
Elisa Zanardi Italy 16 355 1.1× 177 0.8× 420 2.7× 170 1.3× 63 0.7× 56 785
A. Bodurtha Canada 15 376 1.1× 222 1.0× 78 0.5× 90 0.7× 80 0.9× 23 763
Mark Cornfeld United States 11 497 1.5× 294 1.3× 151 1.0× 112 0.9× 48 0.6× 33 838
B. Rovati Italy 16 318 1.0× 219 1.0× 76 0.5× 96 0.8× 36 0.4× 38 651
Avril Mf France 8 169 0.5× 206 0.9× 121 0.8× 89 0.7× 38 0.4× 29 410

Countries citing papers authored by Mary Collier

Since Specialization
Citations

This map shows the geographic impact of Mary Collier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Collier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Collier more than expected).

Fields of papers citing papers by Mary Collier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Collier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Collier. The network helps show where Mary Collier may publish in the future.

Co-authorship network of co-authors of Mary Collier

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Collier. A scholar is included among the top collaborators of Mary Collier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Collier. Mary Collier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Curigliano, Giuseppe, Xavier Pivot, Javier Cortés, et al.. (2013). Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. The Breast. 22(5). 650–656. 73 indexed citations
2.
Kozloff, Mark, Ellen Chuang, Alex Starr, et al.. (2009). An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Annals of Oncology. 21(7). 1436–1441. 40 indexed citations
3.
4.
Heath, Elisabeth I., Barbara Burtness, Lawrence Kleinberg, et al.. (2006). Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma. Investigational New Drugs. 24(2). 135–140. 31 indexed citations
5.
Miller, KD, Anthony Elias, H. S. Rugo, et al.. (2006). SU11248 (sunitinib malate) therapy in patients with refractory metastatic breast cancer: preliminary safety and efficacy results from a phase II study. European Journal of Cancer Supplements. 4(2). 172–172. 6 indexed citations
6.
Miller, Kathy D., HJ Burstein, Anthony Elias, et al.. (2005). Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). Journal of Clinical Oncology. 23(16_suppl). 563–563. 57 indexed citations
7.
Hande, Kenneth R., Mary Collier, Linda J. Paradiso, et al.. (2004). Phase I and Pharmacokinetic Study of Prinomastat, a Matrix Metalloprotease Inhibitor. Clinical Cancer Research. 10(3). 909–915. 37 indexed citations
8.
Bissett, D., Howard L. McLeod, Mary Collier, et al.. (2001). Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034. British Journal of Cancer. 84(3). 308–312. 22 indexed citations
9.
Roberts, John D., Stephen Shibata, Darcy Spicer, et al.. (2000). Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks. Cancer Chemotherapy and Pharmacology. 45(5). 423–427. 14 indexed citations
10.
McLeod, Howard L., J Cassidy, David G. Priest, et al.. (2000). Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034.. PubMed. 6(7). 2677–84. 34 indexed citations
11.
Feun, Lynn G., et al.. (1997). Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder. Investigational New Drugs. 15(2). 157–163. 33 indexed citations
12.
Berlin, Jordan, Amber C. King, Kendra D. Tutsch, et al.. (1994). A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma. Investigational New Drugs. 12(2). 137–141. 9 indexed citations
13.
Feun, Lynn G., et al.. (1994). Oral Piritrexim in Advanced Bladder Cancer. American Journal of Clinical Oncology. 17(5). 448–451. 9 indexed citations
14.
Laufman, Leslie R., et al.. (1993). A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer.. Journal of Clinical Oncology. 11(10). 1888–1893. 44 indexed citations
15.
Vokes, Everett E., Daniel J. Haraf, Rosemarie Mick, et al.. (1992). Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: A feasible and active approach. Annals of Oncology. 3(1). 79–81. 15 indexed citations
16.
Vokes, Everett E., Isaiah W. Dimery, Charlotte Jacobs, et al.. (1991). A phase II study of piritrexim in combination with methotrexate in recurrent and metastatic head and neck cancer. Cancer. 67(9). 2253–2257. 16 indexed citations
17.
Feun, Lynn G., René González, Niramol Savaraj, et al.. (1991). Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration.. Journal of Clinical Oncology. 9(3). 464–467. 30 indexed citations
18.
Feun, Lynn G., Niramol Savaraj, Pasquale Benedetto, et al.. (1991). Phase I Trial of Piritrexim Capsules Using Prolonged, Low-Dose Oral Administration for the Treatment of Advanced Malignancies. JNCI Journal of the National Cancer Institute. 83(1). 51–55. 15 indexed citations
19.
Laufman, Leslie R., Wayne D. Brenckman, Mary Collier, et al.. (1989). Clinical experience with leucovorin and 5-fluorouracil. Cancer. 63(S6). 1031–1035. 23 indexed citations
20.
Laufman, Leslie R., Wayne D. Brenckman, Mary Collier, et al.. (1988). Clinical Experience with CF-FUra. Advances in experimental medicine and biology. 244. 201–211. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by N. J. Vogelzang Breakdown of academic impact, for papers by David D. Gibbs Breakdown of academic impact, for papers by Antonella Ingrosso Breakdown of academic impact, for papers by J. Luz Tovar García Breakdown of academic impact, for papers by Katherine A. Shackelford Breakdown of academic impact, for papers by Elisa Zanardi Breakdown of academic impact, for papers by A. Bodurtha Breakdown of academic impact, for papers by Mark Cornfeld Breakdown of academic impact, for papers by B. Rovati Breakdown of academic impact, for papers by Avril Mf
Rankless by CCL
2026